Correlation of Microbiome and Metabonomics With IgA Nephropathy
ConditionIgA Nephropathy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age16-65
SponsorGuangdong Provincial People's Hospital
About this trial
IgAN is the most prevalent primary glomerulonephritis in China, is characterized by the deposition of IgA1 (particularly, galactose-deficient IgA1) in the glomerular mesangium. Galactosedeficient IgA1, supposed to be produced by Peyer patches in the mucosa-associated lymphoid tissue (MALT), is triggered by exposure to commensal or pathogenic bacteria, involved in the initial step in the pathogenesis of IgAN. Similar to intestinal flora, a disruption in oral flora is closely associated with the occurrence of many malignant tumors and autoimmune diseases. The relationship between oral and throat microflora and the occurrence of IgAN is unclear at present. The aim of the present study was to develop a preliminary model based on mucosa -specific microbes and clinical indicators to facilitate the early diagnosis of IgAN and obtain insights into its treatment.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
(1) Pathological changes of IgAN were confirmed by renal biopsy (2) Age ≥16 years (3) IgA deposition caused by secondary factors such as non-purpura glomerulonephritis, liver cirrhosis, SLE, HIV infection and hepatitis B virus associated nephritis (4) No antibiotics and/or functional foods (probiotics and/or prebiotics) for at least one month prior to sampling (5) No hormone or immunosuppressant treatment in the six months prior to sampling (6) No significant changes in diet or medication for at least one month (7) No other immune or autoimmune diseases, such as systemic lupus erythematosus (8) Signed informed consent
Disqualifiers
Type I or type II diabetes
Pregnancy and menstrual period
Mental illness and inability to assess follow-up
Medically diagnosed intestinal diseases such as irritable bowel syndrome and inflammatory bowel disease
Trial population
IgA nephropathy confirmed by renal biopsy and family members living with them
Trial design
Design model
Case-control
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Number of Participants with all-cause death
Death for any reason.
Time frame
From trial initiation to any event first occurrence,the first to arrive will be evaluated up to 6 months2
Number of Participants with not meet the entry criteria
not meet the entry criteria for any reason
Time frame
From trial initiation to any event first occurrence,the first to arrive will be evaluated up to 6 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov